Literature DB >> 9843416

Identification of specific sites involved in ligand binding by photoaffinity labeling of the receptor for the urokinase-type plasminogen activator. Residues located at equivalent positions in uPAR domains I and III participate in the assembly of a composite ligand-binding site.

M Ploug1.   

Abstract

Plasminogen activation by the urokinase-type plasminogen activator (uPA) is facilitated in the presence of cells expressing the glycolipid-anchored high-affinity receptor for uPA (denoted uPAR). Structures involved in the interaction between human uPAR and a decamer peptide antagonist of uPA binding (SLNFSQYLWS) were previously tagged by specific site-directed photoaffinity labeling [Ploug, M., Ostergaard, S., Hansen, L. B. L., Holm, A., and Dano, K. (1998) Biochemistry 37, 3612-3622]. Replacement of the key functional residues Phe4 and Trp9 with either benzophenone or (trifluoromethyl)aryldiazirine rendered this peptide antagonist photoactivatable, and as a consequence, it incorporated covalently upon photolysis into either uPAR domain I or domain III depending on the actual position of the photophore in the sequence. The residues of uPAR specifically targeted by photoaffinity labeling were identified by matrix-assisted laser desorption mass spectrometry, NH2-terminal sequence analysis, and amino acid composition analysis after enzymatic fragmentation and HPLC purification. According to these data, the formation of the receptor-ligand complex positions Phe4 of the peptide antagonist very close to Arg53 and Leu66 in uPAR domain I and Trp9 of the antagonist in the vicinity of His251 in uPAR domain III. The gross molecular arrangement of the deduced receptor-ligand interface provides a rational structural basis for the observed requirement for the intact multidomain state of uPAR for achieving high-affinity ligand binding, since according to this model ligand binding must rely on a close spatial proximity of uPAR domains I and III. In addition, these data suggest that the assembly of the composite ligand binding site in uPAR may resemble the homophilic interdomain dimerization of kappa-bungarotoxin, a structural homologue of the Ly-6/uPAR domain family.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9843416     DOI: 10.1021/bi981203r

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  11 in total

1.  Direct binding of occupied urokinase receptor (uPAR) to LDL receptor-related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activity.

Authors:  R P Czekay; T A Kuemmel; R A Orlando; M G Farquhar
Journal:  Mol Biol Cell       Date:  2001-05       Impact factor: 4.138

Review 2.  Photoaffinity labeling combined with mass spectrometric approaches as a tool for structural proteomics.

Authors:  David Robinette; Nouri Neamati; Kenneth B Tomer; Christoph H Borchers
Journal:  Expert Rev Proteomics       Date:  2006-08       Impact factor: 3.940

3.  Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide.

Authors:  Paola Llinas; Marie Hélène Le Du; Henrik Gårdsvoll; Keld Danø; Michael Ploug; Bernard Gilquin; Enrico A Stura; André Ménez
Journal:  EMBO J       Date:  2005-04-07       Impact factor: 11.598

4.  The acidic domain of GPIHBP1 is important for the binding of lipoprotein lipase and chylomicrons.

Authors:  Peter Gin; Liya Yin; Brandon S J Davies; Michael M Weinstein; Robert O Ryan; André Bensadoun; Loren G Fong; Stephen G Young; Anne P Beigneux
Journal:  J Biol Chem       Date:  2008-08-18       Impact factor: 5.157

5.  Highly conserved cysteines within the Ly6 domain of GPIHBP1 are crucial for the binding of lipoprotein lipase.

Authors:  Anne P Beigneux; Peter Gin; Brandon S J Davies; Michael M Weinstein; André Bensadoun; Loren G Fong; Stephen G Young
Journal:  J Biol Chem       Date:  2009-09-02       Impact factor: 5.157

Review 6.  Therapeutic potential of siRNA-mediated targeting of urokinase plasminogen activator, its receptor, and matrix metalloproteinases.

Authors:  Christopher S Gondi; Jasti S Rao
Journal:  Methods Mol Biol       Date:  2009

7.  The receptor for urokinase-plasminogen activator (uPAR) controls plasticity of cancer cell movement in mesenchymal and amoeboid migration style.

Authors:  Francesca Margheri; Cristina Luciani; Maria Letizia Taddei; Elisa Giannoni; Anna Laurenzana; Alessio Biagioni; Anastasia Chillà; Paola Chiarugi; Gabriella Fibbi; Mario Del Rosso
Journal:  Oncotarget       Date:  2014-03-30

8.  Mapping the topographic epitope landscape on the urokinase plasminogen activator receptor (uPAR) by surface plasmon resonance and X-ray crystallography.

Authors:  Baoyu Zhao; Sonu Gandhi; Cai Yuan; Zhipu Luo; Rui Li; Henrik Gårdsvoll; Valentina de Lorenzi; Nicolai Sidenius; Mingdong Huang; Michael Ploug
Journal:  Data Brief       Date:  2015-09-04

Review 9.  Structure-driven design of radionuclide tracers for non-invasive imaging of uPAR and targeted radiotherapy. The tale of a synthetic peptide antagonist.

Authors:  Michael Ploug
Journal:  Theranostics       Date:  2013-06-24       Impact factor: 11.556

10.  Cyr61 and YB-1 are novel interacting partners of uPAR and elevate the malignancy of triple-negative breast cancer.

Authors:  Michaela C Huber; Natalie Falkenberg; Stefanie M Hauck; Markus Priller; Herbert Braselmann; Annette Feuchtinger; Axel Walch; Manfred Schmitt; Michaela Aubele
Journal:  Oncotarget       Date:  2016-07-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.